Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.

Date publication

juin 2023

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr DESMOULINS Isabelle , Dr JOUANNAUD Christelle

Tous les auteurs :
Grinda T, Antoine A, Jacot W, Cottu PH, de la Motte Rouge T, Frenel JS, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret Reynier MA, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Pérol D, Pistilli B, Delaloge S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37385070

Résumé

Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity.

Mots clés

Breast cancer, ESME cohort, Overall survival, Real-world data, Triple-negative breast cancer

Référence

Eur J Cancer. 2023 06 7;189:112935